Neuropil < Neuroprotective Agents < Neuropsychological Tests

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 66.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000339 (2015)	Andrew B. West	Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.
000476 (2014)	Robert A. Hauser ; Dee Silver ; Azhar Choudhry ; Eli Eyal ; Stuart Isaacson	Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
000572 (2014)	Abhishek Chandra ; Ashu Johri ; M Flint Beal	Prospects for neuroprotective therapies in prodromal Huntington's disease.
000663 (2014)	Radu Constantinescu ; Jordan Elm ; Peggy Auinger ; Saloni Sharma ; Erika F. Augustine ; Laith Khadim ; Karl Kieburtz	Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.
000682 (2013)	Antje Haehner ; Thomas Hummel ; Martin Wolz ; Lisa Klingelhöfer ; Mareike Fauser ; Alexander Storch ; Heinz Reichmann	Effects of rasagiline on olfactory function in patients with Parkinson’s disease.
000844 (2013)	Katherine L. Possin ; Gail A. Kang ; Christine Guo ; Eric M. Fine ; Andrew J. Trujillo ; Caroline A. Racine ; Reva Wilheim ; Erica T. Johnson ; Jennifer L. Witt ; William W. Seeley ; Bruce L. Miller ; Joel H. Kramer	Rivastigmine is associated with restoration of left frontal brain activity in Parkinson's disease.
000985 (2013)	Fanny Duval ; Olivier Flabeau ; Julien Razafimahefa ; Umberto Spampinato ; François Tison	Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome.
000A74 (2013)	C Warren Olanow ; Patrik Brundin	Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
000A75 (2013)	Fabrizio Stocchi ; C Warren Olanow	Obstacles to the development of a neuroprotective therapy for Parkinson's disease.
000A76 (2013)	C Warren Olanow ; Jose A. Obeso ; Fabrizio Stocchi	The vatican meeting on neuroprotection for Parkinson's disease.
000C59 (2013)	Paolo Calabresi ; Massimiliano Di Filippo ; Antongiulio Gallina ; Yingfei Wang ; Jeannette N. Stankowski ; Barbara Picconi ; Valina L. Dawson ; Ted M. Dawson	New synaptic and molecular targets for neuroprotection in Parkinson's disease.
000C62 (2013)	Pankaj A. Agarwal ; A Jon Stoessl	Biomarkers for trials of neuroprotection in Parkinson's disease.
000C66 (2013)	Anthony E. Lang ; Eldad Melamed ; Werner Poewe ; Olivier Rascol	Trial designs used to study neuroprotective therapy in Parkinson's disease.
000D14 (2013)	Erwan Bezard ; Zhenyu Yue ; Deniz Kirik ; Maria Grazia Spillantini	Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.
000D50 (2012)	Maryka Quik ; Xiomara A. Perez ; Tanuja Bordia	Nicotine as a potential neuroprotective agent for Parkinson's disease.
000E04 (2012)	Johannes R. Streffer ; Igor D. Grachev ; Cheryl Fitzer-Attas ; Baltazar Gomez-Mancilla ; Babak Boroojerdi ; Juliana Bronzova ; Susanne Ostrowitzki ; Stephen J. Victor ; Paulo Fontoura ; Robert Alexander	Prerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective.
000F23 (2011)	Alfonso Fasano ; Alessandro Di Matteo ; Carmine Vitale ; Giovanna Squintani ; Laura Ferigo ; Federica Bombieri ; Gabriella Santangelo ; Marianna Amboni ; Paolo Barone ; Michele Tinazzi	Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy.
001001 (2012)	Charles S. Venuto ; Andrew Mcgarry ; Qing Ma ; Karl Kieburtz	Pharmacologic approaches to the treatment of Huntington's disease.
001027 (2011)	Peter Jenner ; J William Langston	Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.
001038 (2011)	Christopher Kobylecki ; Michael P. Hill ; Alan R. Crossman ; Paula Ravenscroft	Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
001139 (2011)	Elisa Garbayo ; Eduardo Ansorena ; Jose Luis Lanciego ; María Jose Blanco-Prieto ; María S. Aymerich	Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/MedMesh.i -k "Neuroprotective Agents" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/MedMesh.i  \
                -Sk "Neuroprotective Agents" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Corpus
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Neuroprotective Agents
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024